FDA and EMA Submissions, Partnerships, Milestones, Participation Withdrawals, and Prequalifications - Research Report on Johnson

FDA and EMA Submissions, Partnerships, Milestones, Participation Withdrawals,
   and Prequalifications - Research Report on Johnson & Johnson, Novartis,
                AstraZeneca, Astex Pharmaceuticals, and Sanofi

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 10, 2013

NEW YORK, September 10, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Johnson
& Johnson (NYSE: JNJ), Novartis AG (NYSE: NVS), AstraZeneca PLC (NYSE: AZN),
Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), and Sanofi (NYSE: SNY). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On September 3, 2013, Johnson & Johnson announced that its pharmaceutical
research arm, Janssen Research & Development, LLC (Janssen), has submitted a
Biologic License Application (BLA) and a Marketing Authorization Application
(MAA) for siltuximab to the US Food and Drug Administration (FDA) and European
Medicines Agency (EMA), respectively. According to Johnson & Johnson,
siltuximab is used in treating patients with multicentric Castleman disease
(MCD) who are HIV-negative and human herpes virus-8 (HHV-8)-negative. Peter F.
Lebowitz, M.D., Ph.D., Global Oncology Therapeutic Area Head, Janssen,
commented, "We're proud of our work on siltuximab. As a rare disease with a
small patient population, MCD is an area of significant unmet need." Lebowitz
explained, "Siltuximab works by targeting interleukin-6 which appears to be
the critical driver of this disease. By focusing on core biologic mechanisms,
we now have the potential of helping patients with a condition that is
challenging to treat." The Full Research Report on Johnson & Johnson -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-08/JNJ]

--

Novartis AG Research Report

On September 6, 2013, Novartis AG (Novartis) announced its exclusive global
licensing and research collaboration agreement with Regenerex LLC., for use of
the Company's novel Facilitating Cell Therapy (FCRx) platform. The Company
said that the FCRx will broaden the current Novartis cell therapy portfolio,
which includes two novel cell therapy platforms initially being investigated
in hematological malignancies. Dr. Timothy Wright, Global Head Development,
Novartis Pharmaceuticals, stated, "As the field of biomedicine sits on the
cusp of a new transformation, we are excited to announce this agreement which
supports the Novartis leadership position in cell therapy." Wright continued,
"Thirty years ago, Novartis developed ciclosporin, which changed
transplantation treatment paradigms and enabled countless lives to be saved.
Now, this collaboration, along with our internal cell therapy assets, has the
potential to transform medicine once again through innovation." The Full
Research Report on Novartis AG - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-08/NVS]

--

AstraZeneca PLC Research Report

On September 4, 2013, AstraZeneca PLC (AstraZeneca) announced the enrollment
of the first patient in the Phase III clinical programme for olaparib, an
innovative oral poly ADP ribose polymerase (PARP) inhibitor being investigated
for the treatment of BRCA mutated ovarian cancer. According to the Company,
the Phase III SOLO (Study of OLaparib in Ovarian cancer) programme is designed
to determine the benefit, by progression free survival, of olaparib as a
maintenance monotherapy in BRCA mutated ovarian cancer patients who are in
complete or partial response following platinum-based chemotherapy in the
first line setting (SOLO 1), and in the relapsed setting (SOLO 2). Antoine
Yver, Vice President and Head of Oncology in AstraZeneca's Global Medicines
Development unit, stated, "This is a significant milestone for olaparib, and
further evidence of AstraZeneca's commitment to invest in distinctive science
in our core therapy areas, with a particular focus on high unmet need. We feel
olaparib has real potential to significantly improve treatment decisions for
this group of patients who currently have limited options, and to become the
next important product in our growing oncology portfolio." The Full Research
Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-08/AZN]

--

Astex Pharmaceuticals, Inc. Research Report

On September 6, 2013, Astex Pharmaceuticals, Inc. (Astex) announced that its
management team members have withdrawn their participation from the three
banking conferences at which the Company had previously planned to present.
According to Astex, the three conferences were: the Rodman & Renshaw Annual
Global Investment Conference, the Morgan Stanley Global Healthcare Conference,
and the Stifel Healthcare Conference 2013. The Full Research Report on Astex
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-09-08/ASTX]

--

Sanofi Research Report

On September 3, 2013, Sanofi announced that its vaccines division, Sanofi
Pasteur has received a prequalification from the World Health Organization
(WHO) for one of its quadrivalent vaccines, Menomune, which is used to prevent
invasive meningococcal disease. According to the Company, the prequalification
makes Menomune vaccine eligible for purchase by United Nations Agencies.
Olivier Charmeil, President and CEO, Sanofi Pasteur, said, "Sanofi Pasteur's
commitment to help protect against meningococcal disease began almost 40 years
ago with the introduction of a monovalent vaccine that offered protection
against serogroup A and a bivalent vaccine that offered protection against
serogroups A and C." Charmeil added, "Our commitment to remaining at the
forefront of advancing the prevention of meningococcal disease, worldwide,
continues today." The Full Research Report on Sanofi - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.InvestorsReports.com/report/2013-09-08/SNY ]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by an analyst. However, we are only human and are prone
    to make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through analysts, only reviewed
the information provided by Equity News Network in this article or report
according to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

Web address: InvestorsReports.com

SOURCE Investors' Reports

Contact: CONTACT PERSON: Kristi Saunders CONTACT PHONE: +1-315-982-6420 (North
America)